[go: up one dir, main page]

WO2009044380A3 - Formulations contenant des particules d'orlistat à dimension de particule contrôlée - Google Patents

Formulations contenant des particules d'orlistat à dimension de particule contrôlée Download PDF

Info

Publication number
WO2009044380A3
WO2009044380A3 PCT/IB2008/054068 IB2008054068W WO2009044380A3 WO 2009044380 A3 WO2009044380 A3 WO 2009044380A3 IB 2008054068 W IB2008054068 W IB 2008054068W WO 2009044380 A3 WO2009044380 A3 WO 2009044380A3
Authority
WO
WIPO (PCT)
Prior art keywords
particles
particle size
controlled particle
formulations containing
orlistat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2008/054068
Other languages
English (en)
Other versions
WO2009044380A2 (fr
Inventor
Shanmugam Kumar
Girish Karanth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of WO2009044380A2 publication Critical patent/WO2009044380A2/fr
Publication of WO2009044380A3 publication Critical patent/WO2009044380A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des formulations pharmaceutiques comprenant une quantité thérapeutiquement efficace de particules d'orlistat à dimension de particule contrôlée et ayant un support pharmaceutiquement acceptable, les formulations présentant des caractéristiques d'absorption et de dissolution améliorées, et les particules d'orlistat ayant une valeur de D50 non supérieure à environ 120 microns et une valeur de D90 non supérieure à 225 microns.
PCT/IB2008/054068 2007-10-05 2008-10-03 Formulations contenant des particules d'orlistat à dimension de particule contrôlée Ceased WO2009044380A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2091/DEL/2007 2007-10-05
IN2091DE2007 2007-10-05

Publications (2)

Publication Number Publication Date
WO2009044380A2 WO2009044380A2 (fr) 2009-04-09
WO2009044380A3 true WO2009044380A3 (fr) 2010-01-14

Family

ID=40451344

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/054068 Ceased WO2009044380A2 (fr) 2007-10-05 2008-10-03 Formulations contenant des particules d'orlistat à dimension de particule contrôlée

Country Status (1)

Country Link
WO (1) WO2009044380A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL216542B1 (pl) * 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
UA107369C2 (en) * 2010-02-01 2014-12-25 Lab Bago S A Pharmaceutical composition with anti-obesity activity comprising a premixture of pure orlistat and preparation process
KR101833250B1 (ko) 2010-10-25 2018-03-02 한미사이언스 주식회사 저융점 활성 성분을 포함하는 구형 압출과립, 이를 포함하는 경구 투여용 정제 및 이의 제조 방법
JP2015537029A (ja) 2012-11-14 2015-12-24 ダブリュー・アール・グレース・アンド・カンパニー−コーンＷ Ｒ Ｇｒａｃｅ ＆ Ｃｏ−Ｃｏｎｎ 生物学的に活性な物質及び不規則性無機酸化物を含有する組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US20060246141A1 (en) * 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
WO2009039157A2 (fr) * 2007-09-17 2009-03-26 Dr. Reddy's Laboratories Ltd. Formulations pharmaceutiques d'orlistat

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (fr) 1983-06-22 1988-12-28 Paul Hadvary Derives de leucine
DK1105122T3 (da) 1998-08-14 2005-08-08 Hoffmann La Roche Pharmaceutical compositions containing lipase inhibitors
KR100669497B1 (ko) 2005-08-17 2007-01-16 보람제약주식회사 안정성과 용출률이 뛰어난 약리학적 조성물 및 그 제조방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US20060246141A1 (en) * 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
WO2009039157A2 (fr) * 2007-09-17 2009-03-26 Dr. Reddy's Laboratories Ltd. Formulations pharmaceutiques d'orlistat

Also Published As

Publication number Publication date
WO2009044380A2 (fr) 2009-04-09

Similar Documents

Publication Publication Date Title
WO2007062266A3 (fr) Formes galeniques de ganaxolone et procedes de preparation et d'utilisation de celles-ci
WO2007146248A3 (fr) Préparations de laquinimod stables
WO2006084164A8 (fr) Systeme d'administration a retention gastrique et a liberation lente
AU2001275078A1 (en) Bioconjugates of nanoparticles as radiopharmaceuticals
WO2007093642A3 (fr) Formes pharmaceutiques multimicroparticulaires qui resistent a la decharge immediate du principe actif en presence d'alcool
WO2008008733A3 (fr) Formulations de sorafenib nanoparticulaire
WO2007127158A3 (fr) Modification d'absorption percutanée de matériaux topiquement actifs
WO2006085101A3 (fr) Nouvelles compositions pharmaceutiques utiles pour l'administration transmuqueuse de medicaments
WO2007053197A3 (fr) Preparations nanoparticulaires a base d'acetaminophene
WO2007150075A3 (fr) Compositions comprenant du meloxicam nanoparticulaire et de l'hydrocodone à libération contrôlée
WO2007120648A3 (fr) Composes oxycodone mono et di-substitues et compositions correspondantes
WO2009092129A8 (fr) Composition pharmaceutique de duloxétine à libération retardée
WO2009045795A3 (fr) Formulations galéniques de composés organiques
WO2010002613A3 (fr) Procédé de fabrication d’une composition pharmaceutique en poudre sèche
WO2008003050A3 (fr) Formulations de nitrate de gallium
WO2009039157A3 (fr) Formulations pharmaceutiques d'orlistat
WO2009077573A3 (fr) Suspension comprenant des microparticules d'ézétimibe non micronisées
WO2009017193A1 (fr) Préparation granulaire médicinale contenant des acides aminés, très facile à prendre
WO2009044380A3 (fr) Formulations contenant des particules d'orlistat à dimension de particule contrôlée
WO2002015880A8 (fr) Procede de production et d'utilisation de mannitol en poudre et compositions renfermant du mannitol
WO2005117895A3 (fr) Compositions contenant de la meloxicame
WO2008099615A1 (fr) Composition pharmaceutique contenant une suspension à base d'huile en fines particules
WO2007002823A3 (fr) Formulations d'oestrogenes conjugues et de bazedoxifene
WO2007146943A3 (fr) Formulations d'inhibiteurs de kinase nanoparticulaires
WO2007075381A3 (fr) Compositions pharmaceutiques d'ilaprazole

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08807882

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08807882

Country of ref document: EP

Kind code of ref document: A2